Please wait while we load the requested 10-Q report or click the link below:
https://last10k.com/sec-filings/report/1310094/000119312512052836/d280517d10q.htm
July 2013
March 2013
February 2013
November 2012
October 2012
August 2012
June 2012
June 2012
March 2012
March 2012
Document And Entity Information | 3 Months Ended | |
---|---|---|
Dec. 31, 2011 | Jan. 31, 2012 | |
Document And Entity Information [Abstract] | ||
Document Type | 10-Q | |
Amendment Flag | false | |
Document Period End Date | Dec. 31, 2011 | |
Document Fiscal Period Focus | Q1 | |
Document Fiscal Year Focus | 2012 | |
Entity Registrant Name | ACCENTIA BIOPHARMACEUTICALS INC | |
Entity Central Index Key | 0001310094 | |
Current Fiscal Year End Date | --09-30 | |
Entity Filer Category | Smaller Reporting Company | |
Entity Common Stock, Shares Outstanding | 76,041,068 |
Please wait while we load the requested 10-Q report or click the link below:
https://last10k.com/sec-filings/report/1310094/000119312512052836/d280517d10q.htm
Compare this 10-Q Quarterly Report to its predecessor by reading our highlights to see what text and tables were removed , added and changed by Accentia Biopharmaceuticals Inc.
Accentia Biopharmaceuticals Inc's Definitive Proxy Statement (Form DEF 14A) filed after their 2012 10-K Annual Report includes:
CIK: 1310094
Form Type: 10-Q Quarterly Report
Accession Number: 0001193125-12-052836
Submitted to the SEC: Fri Feb 10 2012 4:58:54 PM EST
Accepted by the SEC: Fri Feb 10 2012
Period: Saturday, December 31, 2011
Industry: Pharmaceutical Preparations